Patent Use Code Arguments At Supreme Court Focus On Role Of FDA In Prandin Patent Dispute
This article was originally published in The Pink Sheet Daily
Executive Summary
In oral arguments in Caraco v. Novo Nordisk, justices also ask whether Caraco could have sued FDA for accepting Novo’s Prandin patent use code instead of filing a counterclaim against Novo to force it to change the code.
You may also be interested in...
Patent Use Codes: Will Supreme Court Curb Carve-outs Or Spawn Suits?
The high court hears oral arguments in a case that could limit the ability of generics to carve out still-patented uses from their labeling to get prompt ANDA approval. Brand manufacturers argue that allowing such challenges will invite a flood of lawsuits. Caraco v. Novo revolves around a patent use code for the diabetes drug Prandin.
New Tactic In ANDA Litigation: Novo Blocks Generic Prandin By Changing Its Patent Use Code
Novo Nordisk succeeded in an unusual maneuver in blocking Caraco Pharmaceutical from getting a generic version of its blood glucose-lowering drug Prandin (repaglinide) on the market. It changed the use code on the patent covering the drug in combination with metformin so that Caraco could not get approval for a monotherapy
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.